RxDoctor Payments Data

Francis Geissler

Ophthalmology · Tacoma, WANPI 1386683837

Payments from drug & device makers

$6,236in general payments, 2019–2025

Across 67 payments — averaging $93.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Carl Zeiss Meditec USA, Inc.$4K
  • Rxsight Inc$521
  • Alcon$325
  • Dutch Ophthalmic, USA$305
  • Johnson & Johnson Surgical Vision, Inc.$211
  • Bausch & Lomb Americas Inc.$177
  • plus $719 from 10 others

What the payments were for

  • Speaking & faculty fees$391%
  • Food & beverage$2,22036%
  • Other$3,97864%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,236 in reported general payments places this provider in the 80th percentile of 428 ophthalmology providers in Washington.

See all ophthalmology providers in Washington

Medicare billing

Part B allowed, 2024
$289,802
Medicare patients
1,124
Services billed
2,391

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyzultaLatanoprostene Bunod75$35,120
RestasisCyclosporine49$31,192
Cyclosporine17$13,300
LumiganBimatoprost17$11,099
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol57$10,227
Prednisolone Acetate212$9,752
CombiganBrimonidine Tartrate/Timolol21$7,319
Dorzolamide-TimololDorzolamide/Timolol/Pf48$6,296
SimbrinzaBrinzolamide/Brimonidine Tart24$5,522
Loteprednol Etabonate19$5,273
Latanoprost353$4,096
Travoprost20$2,470
Fluorometholone31$1,997
Timolol Maleate95$1,300
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat82$1,289

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$177$49,60987 claims
Bausch & Lomb Americas Inc.Vyzulta$177$35,12075 claims
AlconSimbrinza$325$5,52224 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$96$5,27319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 428 ophthalmology providers in Washington.

Other ophthalmology in Tacoma

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →